Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL9800685 | 1.00 | CSNK1E (0.50) | CSNK1EMMP1MMP9MMP13KCNH2 | |
| Ammonia Solution, Strong SCHEMBL9326087 | 1.00 | CSNK1E (0.50) | CSNK1EMMP1MMP9MMP13KCNH2 | |
| Ammonia Solution, Strong SCHEMBL1782255 | 1.00 | CSNK1E (0.50) | CSNK1EMMP1MMP9MMP13KCNH2 | |
| Ammonia Solution, Strong SCHEMBL297223 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL5826088 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL2948623 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL1784551 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL875995 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL5183320 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL1840232 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7625581-B2 | Tissue scaffolds for use in muscoloskeletal repairs | ETHICON, INC. (US) | 2009-12-01 | — | — | US | claimed |
| WO-2005039381-A2 | COMPOSITIONS AND PROCESSES FOR ANALYSIS OF PHARMACOLOGIC AGENTS IN BIOLOGICAL SAMPLES | DRUG RISK SOLUTIONS, L.L.C. (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050037386-A1 | Composition and processes for analysis of pharmacologic agents in biological samples | DRUG RISK SOLUTIONS, L.L.C. | 2005-02-17 | — | — | US | claimed |
| US-5994073-A | USING 1,2-DIOXETANES AS REPORTER MOLECULES, E.G., SUBSTRATES FOR ENZYME-BOUND TARGET AQUEOUS ASSAYS AND INCLUDING A CATIONIC POLYMER OF A VINYL QUATERNARY SALT AND A DETERGENT; SENSITIVITY; BY-PRODUCT INHIBITION | TROPIX, INC. (US) | 1999-11-30 | — | — | US | claimed |
| EP-4539857-B1 | SUBLINGUAL FORMULATION OF CLADRIBINE FOR USE IN THE TREATMENT OF AUTOIMMUNE NEURODEGENERATIVE DISEASES | VEKTOR PHARMA TF GMBH (DE) | 2026-03-11 | — | — | EP | disclosed |
| US-20260000606-A1 | Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases | VEKTOR PHARMA TF GMBH (DE) | 2026-01-01 | — | — | US | disclosed |
| US-20250375533-A1 | Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases | VEKTOR PHARMA TF GMBH (DE) | 2025-12-11 | — | — | US | disclosed |
| EP-4119124-B1 | MICROEMULSION CONTAINING ORALLY DISINTEGRATING FILM COMPOSITIONS WITH ADJUSTABLE PHYSICAL AND RHEOLOGICAL PROPERTIES | VEKTOR PHARMA TF GMBH (DE) | 2025-10-01 | — | — | EP | disclosed |
| EP-4539857-A1 | SUBLINGUAL FORMULATION OF ANTICANCER COMPOUND FOR USE IN THE TREATMENT OF AUTOIMMUNE NEURODEGENERATIVE DISEASES | Vektor Pharma TF GmbH (DE) | 2025-04-23 | — | — | EP | disclosed |
| US-12097475-B2 | Microfluidic system | THE UNIVERSITY OF CHICAGO (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240192707-A1 | MICROFLUIDIC SYSTEM | THE UNIVERSITY OF CHICAGO | 2024-06-13 | — | — | US | disclosed |
| EP-4370094-A1 | ORALLY DISINTEGRATING FILM COMPOSITION COMPRISING BUPRENORPHINE | G.L. Pharma GmbH (AT) | 2024-05-22 | — | — | EP | disclosed |
| US-20030061687-A1 | High throughput screening of crystallization materials | CALIFORNIA INSTITUTE OF TECHNOLOGY, A CALIFORNIA CORPORATION | 2003-04-03 | — | — | US | disclosed |
| WO-2002082047-A2 | HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION OF MATERIALS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2002-10-17 | — | — | WO | disclosed |
| EP-0707489-A4 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS INC (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0707489-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | Scotgen Biopharmaceuticals, Inc. (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5370955-A | Interfacial polymerization of aryl amine diol dissolved in alkaline aqueous phase with bifunctional acid halide dissolved in water immiscible organic solvent | XEROX CORPORATION (US) | 1994-12-06 | — | — | US | disclosed |
| WO-1994025053-A1 | ATHEROSCLEROTIC PLAQUE SPECIFIC ANTIGENS, ANTIBODIES THERETO, AND USES THEREOF | SCOTGEN BIOPHARMACEUTICALS, INC. (US) | 1994-11-10 | — | — | WO | disclosed |
| WO-1994021821-A1 | IMPROVED ENHANCEMENT OF CHEMILUMINESCENT ASSAYS | TROPIX, INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| WO-1992017614-A1 | COPPER ION FLOTATION WITH CATIONIC REAGENTS | THE BROKEN HILL PROPRIETARY COMPANY LIMITED (AU) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375533-A1 | Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases | BCL9, BCL9L, BCL6B | CSNK1E 2102/4885MMP1 3298/4885MMP9 2697/4885 |
| US-20260000606-A1 | Sublingual Formulation of Anticancer Compound for Use in the Treatment of Autoimmune Neurodegenerative Diseases | BCL9, MALT1, BCL9L | CSNK1E 673/4885MMP1 1945/4885MMP9 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.